Mallampati et al. [52] demonstrated that the inhibition of JAK activity in combination with BCR–ABL inhibition can effectively short-circuit mesenchymal stem cell-mediated TKI resistance, which provided a mechanistic rationale for the current and previous pre-clinical studies suggesting that cotreatment with a second-generation TKI and a JAK inhibitor may be more effective in eradicating LPCs in Ph+ALL. Here, BCR is linked to acute lymphoblastic leukemia.